The future of CF treatment, particularly for individuals with less common CFTR variants, will depend on readily available patient-derived CFTR-expressing cells for use in preclinical testing; this iPSC platform offers several potential advantages that will complement existing cell and animal models of CF. The gene discussed is CFTR; the disease is cystic fibrosis.